{"id":"W2146264128","doi":"10.1056/nejmoa1504720","title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12000,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Placebo; Confidence interval; Relative risk; Diabetes mellitus; Stroke (engine); Angina; Type 2 diabetes; Cardiology; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}